that you did, even on a product against itself, would probably be likely to pass. I mean, it becomes so sensitive and the signal becomes so small, when you subtract most of that signal away, that certainly two lots of the same product would be unlikely to pass if you did that study with any kind of reasonable number of subjects.
So on the other end, any tests you do should both discern the differences that you're interested in, yet not fail products that are almost if not identical. I mean, that's an unreasonable test if you fail a product against itself.
So the magnitude of the baseline is a characteristic when you look at a new drug substance or a new endogenous substance, that you really have to look at.
Obviously, it increases the difficulty of accounting for the baseline if there are feedback mechanisms, as there are with most hormones, that change the baseline with differences in doses or differences in blood levels. So that becomes a significant problem in how best to construct a baseline subtraction scheme when you have a feedback mechanism.
So finally, I guess it's not really a question